SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced that Chief Executive Officer Steven Quay, M.D., Ph.D., will speak at the Noble Capital Markets Emerging Growth Healthcare Conference on Wednesday, April 17 at 9:00 am ET. The presentation will be available virtually and members of the Company's leadership team will be available for one-on-one meetings with registered investors of the conference. Atossa is a clinical stage biopharma ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced promising safety and efficacy data from the Company's Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial. The EVANGELINE study is evaluating (Z)-endoxifen as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. Atossa is a clinical stage b ...

Proactive团队 - Emily Jarvie在澳大利亚和加拿大从事政治新闻和商业报道[1] - Proactive的新闻团队遍布全球金融和投资中心[2] - Proactive团队专注于中小市值市场，同时也关注蓝筹公司、大宗商品和更广泛的投资故事[3] - Proactive团队提供关于生物技术和制药、矿业和自然资源、电池金属、石油和天然气、加密货币以及新兴数字和电动汽车技术等市场的新闻和独特见解[4]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION | --- | --- | |--------------------------------------------------------------|------------------------------------------------------------------------------| | Commission File \nATOSSA (Exact name of registrant | Number: 001-35610 \nTHERAPEUTICS, INC. specified in its charter) | | Delaware | 26-4753208 | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | | --- | --- | --- | --- | | ...

Exhibit 99.1 Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update • Fully enrolled two Phase 2 studies with data from both expected in the second half of 2024 • First patient dosed in new Phase 2 breast cancer prevention study • Data from ongoing Phase 2 EVANGELINE study scheduled to be presented at 2024 AACR Annual Meeting • Ended 2023 with $88.5 million of cash and cash equivalents and no debt SEATTLE, April 1, 2024— Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

(Z)-endoxifen的疗效 - Atossa Therapeutics, Inc.宣布一名乳腺癌患者在接受(Z)-endoxifen治疗五年后仍然没有癌症复发[1] - (Z)-endoxifen有望改变目前乳腺癌治疗范式，减少患者对目前标准治疗的不良反应[2] FDA批准 - FDA批准了一项单病例研究，允许该患者在手术前20天接受4mg/天的(Z)-endoxifen治疗[5] (Z)-endoxifen的特性 - (Z)-endoxifen是tamoxifen的最活跃代谢产物，具有抗雌激素效果，同时对PKCβ1具有靶向作用[12]

Leo Grieco - Leo Grieco拥有波恩茅斯大学传媒制作学位，擅长视频编辑和制作[1] Proactive新闻团队 - Proactive的新闻团队遍布全球主要金融和投资中心，设有办事处和工作室[2] Proactive关注领域 - Proactive专注于中小市值市场，同时也关注蓝筹公司、大宗商品和更广泛的投资故事[3] Proactive提供内容 - Proactive团队提供市场上跨领域的新闻和独特见解，包括生物技术和制药、矿业和自然资源、电池金属、石油和天然气、加密货币以及新兴数字和电动汽车技术[4]